Myc 102

Drug Profile

Myc 102

Alternative Names: Myc102; Mycobactovir

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LTN Pharm; TGV-Laboratories
  • Developer LTN Pharm; National Institutes of Health (USA); TGV-Laboratories; University of Texas Health Science Center at San Antonio
  • Class Antifungals
  • Mechanism of Action Chitin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pneumonia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dermatomycoses; Mycoses; Vulvovaginal candidiasis
  • Phase II Gingivitis; Periodontitis
  • Preclinical Candidiasis; Pneumonia
  • Research Aspergillosis; Cryptococcosis; Onychomycosis

Most Recent Events

  • 07 Jun 2018 Phase-III clinical trials in Vulvovaginal candidiasis in Europe (PO) prior to June 2018
  • 07 Jun 2018 Efficacy data from a phase III trial in Vulvovaginal candidiasis presented at the American Society for Microbiology's Microbe 2018 (ASMM-2018)
  • 22 Aug 2017 Preclinical development is still ongoing Fungal pneumonia in Russia (Inhalation) (TGV Laboratories pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top